INTRODUCTION
Considerable controversy has surrounded the gradual elucidation of the relationship between the different components of the mechanism whereby mitochondria transfer long-chain acyl moieties from the cytosol into the matrix. Although it has been recognized for a considerable time [1, 2] that two carnitine acyltransferases are required on either side of the permeability barrier to acyl-CoA esters presented by the inner membrane, the molecular identity or otherwise between these two transferases [overt (I) and latent (II)] has been disputed. The more amenable of the two transferases to characterization, carnitine palmitoyltransferase (CPT) II, was purified to homogeneity in several laboratories, and, more recently, its complete nucleotide sequence was described for the rat and human liver enzyme [3, 4] . It has a molecular size of approx. 69000.
Parallel progress on elucidation of the structure of CPT I has been hampered by the difficulty in solubilizing this protein from the mitochondrial outer membrane and by the hitherto unsuccessful attempts to raise specific antibodies against it (see [5] ). Polyclonal antibodies raised against CPT II have been variously found to precipitate all CPT activity in solubilized mitochondria [6] and outer membranes [7] , but not to react with any proteins on Western blots after SDS/PAGE of detergent-solubilized mitochondrial outer membranes enriched in CPT I activity [8] .
Consequently, disparate conclusions about the similarity between the two proteins have been reached. Indirect evidence that CPT I and CPT II have different molecular sizes was obtained from observations that irreversible inhibitors of CPT I, such as tetradecylglycidyl-CoA (TDG-CoA) and etomoxir, bind to a protein of Mr -90000 [9] [10] [11] in isolated mitochondria, whereas pure CPT II has an Mr of 69000 (see above). This evidence is indirect as it relies on the (not implausible) assumption that [3H]TDG-CoA binds at the active site of CPT I [10] . It has also been shown [11] that [3H]etomoxir binding capacity co-elutes with CPT activity when octyl glucoside extracts of outer membranes are chromatographed on hydroxyapatite, but these fractions contained many different proteins and no definitive conclusion could be reached about the identity of the two proteins (i.e. [3H]TDG-CoA-binding protein and CPT I). Indeed, some authors [12] claim that the [3H]TDG-CoA-binding protein is a regulatory subunit of CPT I which, in vivo, binds malonylCoA. The catalytic entity represented by CPT I has been repeatedly claimed to have an Mr of -69000 by several groups [7, 13, 14] .
Direct experimental evidence that the two catalytic entities of the transferase system, i.e. CPT I and CPT II, do have different molecular sizes was finally obtained using target size analysis by radiation inactivation [15, 16] . Using this technique we confirmed that CPT II has an Mr of approx. 69 000, and further showed that Abbreviations used: CPT, carnitine palmitoyltransferase; TDG-CoA, acyltransferase.
Vol. 282 tetradecylglycidyl-CoA; PBS, phosphate-buffered saline; COT, carnitine 415 M. P. Kolodziej and others CPT I has an Mr between 83000 [16] and 97000 [15] . This size for CPT I places it within the range observed by others for the [3H]TDG-CoA-binding protein [9] [10] [11] . These experiments constituted strong evidence that the CPT I catalytic and TDG-CoAbinding activities reside in the same protein. However, direct experimental proof of this has not been possible because of the difficulty hitherto encountered in preparing an antibody against either the TDG-CoA-binding protein or CPT I catalytic activity [5] .
The aims of the present study were, therefore, two-fold: first, to develop and characterize an antibody raised against the TDGCoA-binding protein and test whether this also recognizes CPT I, and secondly, to use the antibody to study the immunological relationship between CPT I isoforms in different rat tissues. The results provide the strongest evidence yet that CPT I and the TDG-CoA-binding protein are identical and that immunologically distinct isoforms of CPT I occur in different tissues. We also demonstrate that the anti-(CPT I) antibody does not crossreact with CPT II.
MATERIALS AND METHODS

Animals
Wistar rats were used (see [15] ), and were maintained on a commercial chow diet [15] . Outer membranes for electrophoretic separation of CPT I were prepared from male rats (450-550 g) that had been starved for 48 h. Mitochondria for immunoquantification of CPT I were prepared from female rats (160-350 g) in various (patho)physiological states, as indicated. Diabetes (blood glucose > 25 mM) was induced by intraperitoneal injection of streptozotocin (80 mg/kg body wt.) 72 h before use.
Preparation of mitochondria and outer membranes
All of the liver mitochondrial preparations involved differential centrifugation followed by density gradient purification on gradients generated in 31 % Percoll (see [16, 17] ). After removal of the Percoll by washing, the mitochondria either were used for SDS/PAGE (for quantification of CPT I, see below) or were processed further for the purification of outer membranes. This was performed as described previously [17] and included the Sepharose-cytochrome c affinity purification step. Mitochondria from other tissues were prepared by differential centrifugation according to methods described previously (brain [18] , heart [19] , skeletal muscle [20] , kidney [21] , mammary gland [22] , brown adipose tissue [23] and white adipose tissue [24] 30 s of sonication every 10 min). The extract was treated with Sepharose-concanavalin A (0.2 ml/ml of extract). After separation of the Sepharoseconcanavalin A by centrifugation (500 g, 5 min), the proteins in the soluble phase were disaggregated and electrophoresed, as described above. With practice it was possible to identify the band corresponding to the protein without prior labelling with TDG-CoA in unfixed gels in which the protein bands were visualized after soaking in 0.25 M-KCI [25] . Routinely, approx. 1 ,ug of protein was obtained from 4-6 mg of outer membrane protein. To raise antiserum, the band was excised from several preparative scale gels and the protein was electroeluted into buffer containing 25 mM-Tris, 190 mM-glycine and 0.1 % SDS (pH 8.3). After conjugation of the protein to keyhole limpet haemocyanin using glutaraldehyde [26] , it was used to immunize a sheep using standard techniques. A sample of pre-immune serum was obtained prior to starting the injections of the animal with antigen. CPT II was purified from rat liver mitochondria as described previously [7] and a polyclonal antibody was raised in a sheep using standard techniques.
Preparation of IgG fraction and affinity purification
Immune and pre-immune sera were treated with (NH4)2SO4 to remove albumin and other non-IgG proteins. The insoluble protein was removed by centrifugation at 10000 g for 30 min.
The IgG in the supernatant was precipitated with (NH4)2SO4 and the final pellet was suspended in phosphate (10 mM)-buffered saline, pH 7.4 (PBS), and dialysed against the same medium.
Aliquots of the final protein solution were diluted 1:100 with PBS containing 0.20 fat-free dried milk powder. This solution was incubated either for 2-3 h at room temperature or for 16 h at 4 'C with nitrocellulose strips on to which the antigen had been electroblotted from preparative SDS/PAGE gels [27] . After washing, the antibody bound to the nitrocellulose strips was eluted with 0.2 M-glycine (pH 2.8) by incubation at room temperature for 2 h, and neutralized to pH 7.0 using NaOH. Protease inhibitors (0.1 mM-phenylmethanesulphonyl fluoride, and 1 ,ug each of antipain, pepstatin and leupeptin/ml) were added, and the mixture was dialysed against PBS at 4 'C for 16 h. The dialysed material was concentrated, using Centricon-100 microconcentrators, centrifuged at 2000 g for the required time, and stored at -20°C.
Detection and quantification of CPT I on Western blots
The component proteins of rat liver mitochondria prepared and purified from rats in different physiological states were separated by SDS/PAGE. After blotting on to nitrocellulose (Highbond C-extra; Amersham), a standard quantity of sheep IgG was spotted on to the blot for calibration purposes. The blots were then blocked with 20% fat-free milk protein in PBS and washed. They were incubated with affinity-purified antibody Antibody to liver carnitine palmitoyltransferase solution (1: 100) in PBS containing 0.2 % fat-free dried milk for 2 h at room temperature, and washed thoroughly with PBS. The blots were then placed in 50 ml of PBS containing 125I-labelled Protein G (500 000 c.p.s.) and incubated at room temperature for 2 h. Finally they were washed, dried and exposed to Kodak XOmat AR film overnight at -80 'C. The immunoreactive bands and the IgG standards were localized and excised for counting. Appropriate blanks were obtained concurrently. The linearity of the response was ascertained by electrophoresing at least two concentrations of each protein sample.
Reaction of antibody with CPT I in detergent extracts of outer membranes Purified outer membranes were solubilized by incubation (I h at 0 'C, 3 x 20 s periods of sonication) in a medium containing 10 mM-octyl glucoside, 150 mM-KCl, 5 mM-Tris (pH 7.4), 1 mM-EGTA and protease inhibitors (see above). The unsolubilized membrane material was removed by centrifugation at 100000 g for 30 min. Aliquots of the supernatant were incubated with increasing amounts of anti-(CPT I) IgG or PBS. The incubations were performed in the presence of 10 mM-octyl glucoside for 1 h at 20 'C. A suspension (0.1 ml) of Sepharose-Protein G was added and the incubation was continued for a further 30 min, followed by centrifugation at 1000 g for 10 min to sediment the Sepharose. The activity of CPT I remaining in the supernatant was assayed radiochemically (see below). Parallel experiments, in which identical quantities of purified IgG fraction obtained from pre-immune serum were used, served as controls.
Assay of CPT I and CPT II activities
These were all performed radiochemically. Overt CPT (CPT I) activity was measured in the direction of palmitoylcarnitine synthesis in intact mitochondria, using palmitoyl-CoA as substrate. The assay conditions were: 150 mM-KCl, 5 mM-Tris (pH 7.4), 1 mM-EGTA, 1 mM-dithiothreitol, 5 mM-MgCl2, 5 mM-ATP, 100,uM-palmitoyl-CoA, 0.13% fatty acid-free albumin, 1 ,ug of rotenone/ml and 1 ,tg of antimycin A/ml. Mitochondria (1-2 mg) were added to the assay medium (final volume 2.0 ml) at 37 'C and incubations were continued for 2 min before addition of [3H]carnitine (0.5 mM, 0.5 Ci/mol) to start the reaction. Assays were performed for 1-2 min and terminated by addition of0.3 ml of 6 M-HCl. The [3H]palmitoylcarnitine formed was quantified as described previously [28] . CPT II activity was measured in Tween-20 extracts of whole mitochondria. Known amounts of purified mitochondria (1-2 mg of protein) were treated with Tween-20 (3,u1 of detergent/mg of protein) for 40 min at 0 'C, with two periods (10 s) of sonication. This treatment was found to solubilize all CPT II activity but no CPT I activity by immunoblots (results not shown), as expected from previous observations [8] . The subsequent assay of CPT II activity in the supernatant was performed as described above.
Other assays
The purity of outer membrane preparations was routinely checked by assay of catalase, uricase, NADPH-cytochrome c reductase, monoamine oxidase and succinate dehydrogenase, as described previously [18] . No 
Materials
These were as described previously [15, 17] Sigma (Poole, Dorset, U.K.). 125I-labelled Protein G was prepared as described in [29] .
[3H]TDG-CoA was synthesized as described in [30] , except that [11,12( by mass spectrometry and i.r. spectroscopy as described in [30] . The CoA ester was synthesized as described by [30] .
RESULTS AND DISCUSSION
Labelling of purified rat liver mitochondrial outer membranes with [3H]TDG-CoA resulted in the detection of a single radioactive band (Mr approx. 88000) on fluorographs of SDS gels on which the proteins were separated (Fig. 1 ). This size was very similar to that quoted for the [3H]TDG-CoA binding protein of rat liver by several other workers [9] [10] [11] and to the size of the CPT I catalytic activity determined by target size analysis [15, 16] Effects of antibody on CPT I activity in outer membrane extracts A sheep polyclonal antibody was raised against p88 and an IgG fraction was prepared and affinity-purified (see the Materials and methods section). Preliminary experiments indicated that the antibody did not inactivate CPT I catalytic activity. Consequently, we had to use a method to test for immunoreactivity which did not depend on neutralization of catalytic activity. Because of incomplete solubilization of membranes by any of the detergents tested, it was also not possible to quantify immunoprecipitation directly. Thus we used Sepharose-Protein G treatment to remove from solution the antigen-antibody complex after mild centrifugation. When incubated with octyl glucoside extracts of purified outer membranes, the IgG fraction from the immunized sheep caused the loss of CPT I activity in the supernatant after Sepharose-Protein G treatment (Fig. 2) [15, 16] . 
Immunoreactivity on Western blots
The antibody recognized CPT I strongly on Western blots of protein from outer membranes and of whole mitochondrial extracts even at a 1:10000 dilution (Fig. 3) . At these concentrations it failed to detect any protein in the region of Mr 69000, which is the size of CPT II [6] [7] [8] . However, the antibody cross-reacted faintly with at least two other proteins, of Mr -76000 and -53000 (see also Fig. 1 ). As CPT II would be expected to be present in whole mitochondrial protein, Fig. 4 illustrates that anti-(CPT I) is specific for the outer enzyme and does not cross-react with CPT II. In support of this, antibody raised against CPT II recognized the purified 69000-Mr protein (Fig. 4, lane 5) and recognized CPT II in whole mitochondria (lane 1), but failed to recognize CPT I in either whole mitochondrial or outer membranes (Fig. 4) . No CPT II was detectable in our outer membrane preparations using anti-(CPT II) antibody (Fig. 4, lane 2) . starved/pregnant (-) and weaned (0) female rats were separated by SDS/PAGE and the amount of p88 detected by the antibody was quantified using "25I-Protein G. The blots were exposed to photographic film and the bands migrating in the position of the TDGCoA binding protein were localized and excised for counting of the associated radioactivity. CPT I activity was measured in the same (freshly prepared) mitochondrial samples used for electrophoresis.
A faint band was detected at the same position as CPT I in peroxisomes (Fig. 4, lane c) . As the carnitine acyltransferase (COT) of peroxisomes has an Mr of -60000 [31] , this faint reaction is thought to represent a minor contamination of the peroxisomal fraction with outer membranes. The absence of an immunoreactive band in the 60000-Mr region further suggests that CPT I and peroxisomal COT are immunologically distinct. By contrast, anti-(CPT II) recognized the 60000-Mr band of the peroxisomal enzyme more strongly (Fig. 4, lane 3) , suggesting that there is greater immunological similarity between CPT II and the peroxisomal enzyme than between CPT I and either of the other two enzymes.
When immunoquantification of the band of Mr 88000 was performed using anti-(CPT I) followed by '25I-Protein G (using the same mitochondrial preparations as above), a highly significant positive correlation was obtained when 1251 associated with p88 was plotted against CPT I activity measured in these purified mitochondria (Fig. 5) . This observation again confirms that antibody raised against the TDG-CoA-binding protein is also an anti-(CPT I) antibody.
Because of the relative closeness of the Mr -% 76000 band [detected by anti-(CPT I) at low dilution] and the value of 68000 Mr as the size of CPT II, it was essential to prove conclusively that the Mr ' 76000 band was not CPT II. Therefore purified mitochondria were prepared from livers of animals in various (patho)physiological states that were known to result in a sizeable range of CPT II expression. The activity of the enzyme was measured (see the Materials and methods section) and the amount of immunoreactive protein of Mr -76000 was measured using 125I-labelled Protein G. As can be seen from Fig.  6(a) , the two parameters were not positively correlated. Indeed, there was a modest degree of negative correlation, thus proving that the Mr % 76000 band was not CPT II and that anti-(CPT I) did not detect CPT II on Western blots. As expected, there was a strong correlation between CPT II activity and 1251 associated with the Mr 68000 protein detected by anti-(CPT II) (Fig. 6b) .
The identity of the Mr -. 76 000 and Mr -53 000 proteins must remain speculative at present. It is possible that these two outer membrane proteins also utilize long-chain acyl-CoA as substrate and would thus have some commonality of epitopes with CPT I due to the acyl-CoA binding site. In this respect, long-chain acylCoA synthetase (EC 6.2.1.3; Mr -78000 [32] ) and glycerol phosphate acyltransferase (EC 2.3.1.15; Mr -54000 [33] ) both occur in the mitochondrial outer membrane and may, therefore, also have common outer membrane anchoring domains.
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, ' s . , . from different rat tissues A duplicate blot to that generated for the data shown in Fig. 7 was prepared and probed with anti-(CPT II). Lane 1, heart; 2, skeletal muscle; 3, foetal liver; 4, adult liver; 5, kidney;, 6 , white adipose tissue; 7, brown adipose tissue; 8, mammary gland; 9, brain.
Detection of CPT I in various rat tissues Mitochondria were prepared from eight different adult rat tissues and from foetal liver. Equivalent amounts of mitochondrial protein from each tissue were loaded on to SDS gels, and the relevant blots were probed with either anti-(CPT I) or anti-(CPT II) antibodies. Optimal sensitivity was obtained by detecting the immunoreactive bands using 125I-Protein G. It can be seen (Fig. 7) that only kidney cortex mitochondria contain a strongly reactive CPT I detectable by the antibody raised against liver CPT I.
The extract from heart showed a very weakly reacting band that was about 3000-Mr smaller than the CPT I in liver. This size corresponds to the smaller [3H]TDG-CoA-binding protein described previously [8] . Thus, although rat heart mitochondria express higher CPT I activity per mg of protein than do liver mitochondria [34] (see also below), the heart enzyme is very weakly detected by anti-(rat liver CPT I). This suggests that liver and heart CPT I enzymes are largely immunologically distinct proteins. The same holds for the enzyme from skeletal muscle. This observation is highly significant. First, it has been known for some time that the rat liver enzyme has very different kinetic characteristics (with respect to malonyl-CoA inhibition [34] and Km for carnitine [35] ) from those of the enzymes in heart and skeletal muscle mitochondria. Secondly, the [3H]TDG-CoAbinding protein in these latter two tissues was shown to be smaller than that in the liver [8] . The present data demonstrate that these differences are due to the fact that the proteins that catalyse the CPT I reaction in the two sets of tissues are sufficiently different to be distinguished immunologically. This is probably also the case for CPT I in brown adipose tissue. The activity of the enzyme in mitochondria from brown adipose tissue is expected to be high, and yet the antibody reacted very weakly with protein in the 85000 90000-Mr region (Fig. 7) . The presence of appreciable acylcarnitine-metabolizing capacity in these mitochondria was indicated by the large amounts of immunoreactive CPT II observed when the equivalent blots were probed with anti-(CPT II) (Fig. 8) . Interestingly, brain mitochondria appear to contain the same immunological isoforms as do heart and skeletal muscle mitochondria. No conclusions could be reached about the form of CPT I in mammary gland and white adipose tissue, as the amounts of CPT I (and of CPT II) were evidently too low to be detectable.
In the more lipogenic tissues, the Mr -76000 band was particularly prominent, suggesting that this indeed represents a protein involved in the lipogenic pathway (see above). The Mr 53000 protein was also fairly abundant in these tissues. An additional band (Mr -55 000) was detected by anti-(CPT I) only in mitochondria from mammary tissue.
Foetal rat liver mitochondria were studied because it has been suggested [36] that CPT I in these mitochondria may be of a different type from that in adult liver. However, it is evident that these mitochondria contain CPT I of an identical size and immunoreactivity as that in adult liver. Fig. 8 also illustrates that, as expected from the data reported in [5] , CPT II in all the tissues tested had the same Mr (approx. 68000). However, it was noticeable that for an equivalent quantity of mitochondrial protein, much fainter reactions with anti-(CPT II) antibody were obtained with mitochondria obtained from kidney cortex, white adipose tissue, mammary gland and brain. Whereas it is possible that for the latter three tissues this may be related to the low fatty acid-oxidizing capacity of these mitochondria, the same is not likely to hold for kidney cortex mitochondria. This raises the prospect that, although CPT II in all rat tissues may be of approximately the same Mr' there may be immunologically distinct isoforms in different tissues.
Conclusions
We have developed a polyclonal antibody which reacts with rat liver mitochondrial CPT I. As the antibody was raised initially against the TDG-CoA-binding protein of rat liver mitochondria, the data strongly suggest that CPT I is also the TDG-CoA-binding protein. We have shown that CPT I in liver is immunologically distinct from that in heart and skeletal muscle, and probably also from that in brown adipose tissue, whereas CPT I in liver is identical to that found in kidney mitochondria. CPT I was shown to be immunologically distinct from CPT II using antibodies raised against the respective proteins. The development of the antibody against CPT I should provide excellent prospects for the resolution of the question as to whether malonyl-CoA binds to the CPT I protein itself or to a regulatory subunit, as well as for the further elucidation of the structure of CPT I itself.
